Nusinersen

Reviewed on 9/3/2021

Brand Name and Other Names: Spinraza

Generic Name: Nusinersen

Drug Class: Neurologics, Antisense Oligonucleotides

What Is Nusinersen Used For and How Does it Work?

Nusinersen is used for spinal muscular atrophy (SMA) in children and adults.

Nusinersen is available under the following different brand names: Spinraza.

What Are the Dosages of Nusinersen?

Dosages of Nusinersen:

Dosage Forms and Strengths

Solution for Intrathecal Injection

  • 12mg/5mL single-dose vial

Dosage Considerations – Should be Given as Follows:

Spinal Muscular Atrophy

  • Indicated for spinal muscular atrophy (SMA) in children and adults
  • 12 mg intrathecally per administration
  • Initial: 4 loading doses; administer the first 3 doses at 14-day intervals and the fourth dose 30 days after the third dose
  • Maintenance: One dose every 4 months
  • Safety and effectiveness have been established in children aged newborn to 17 years

Dosage Considerations – Should be Given as Follows:

Laboratory tests

SLIDESHOW

Brain Food Pictures: What to Eat to Boost Focus See Slideshow

What Are Side Effects Associated with Using Nusinersen?

Common side effects of Nusinersen include:

Postmarketing side effects of nusinersen reported include:

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

What Other Drugs Interact with Nusinersen?

  • Nusinersen has no listed severe interactions with other drugs.
  • Nusinersen has no listed serious interactions with other drugs.
  • Nusinersen has no listed moderate interactions with other drugs.
  • Nusinersen has no listed mild interactions with other drugs.

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist. Check with your physician if you have health questions or concerns.

What Are Warnings and Precautions for Nusinersen?

Warnings

  • This medication contains nusinersen. Do not take Spinraza if you are allergic to nusinersen or any ingredients contained in this drug.

Contraindications

  • None

Effects of Drug Abuse

  • No information is available.

Short-Term Effects

  • See "What Are Side Effects Associated with Using Nusinersen?"

Long-Term Effects

  • See "What Are Side Effects Associated with Using Nusinersen?"

Cautions

Coagulation

  • Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides
  • Obtain platelet count and coagulation laboratory testing at baseline and before each administration and as clinically needed

Renal toxicity

  • Nusinersen is present in and excreted by the kidney
  • Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides
  • Conduct quantitative spot urine protein testing (preferably using a first-morning urine specimen) at baseline and before each dose
  • For urinary protein concentration greater than 0.2 g/L, consider repeat testing and further evaluation

Re-elevation of coagulation parameters

  • In a limited number of patients in the clinical program, between 12-24 hours after administrating nusinersen 5 g, elevated coagulation parameters (e.g., aPTT, ECT) have been observed
  • If reappearance of clinically relevant bleeding together with elevated coagulation parameters is observed after administering nusinersen 5 g, administration of an additional 5 g dose may be considered
  • Similarly, patients who require a second emergency surgery/urgent procedure and have elevated coagulation parameters may receive an additional 5-g dose
  • The safety and effectiveness of repeat treatment with nusinersen have not been established

Pregnancy and Lactation

  • There are no adequate data on the developmental risk associated with the use of nusinersen in pregnant women. No adverse effects on embryofetal development were observed in animal studies in which nusinersen was administered by subcutaneous injection to mice and rabbits during pregnancy. Consult your doctor.
  • It is unknown if nusinersen is distributed in human breast milk. Nusinersen is detected in the milk of lactating mice when administered by subcutaneous injection. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for nusinersen, and any potential adverse effects on the breastfed infant from the drug or the underlying maternal condition.

QUESTION

The abbreviated term ADHD denotes the condition commonly known as: See Answer
References
https://reference.medscape.com/drug/spinraza-nusinersen-1000135

Health Solutions From Our Sponsors